The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 9

From BugSigDB


Needs review

Curated date: 2024/11/22

Curator: KateRasheed

Revision editor(s): KateRasheed

Subjects

Location of subjects
Austria
United Kingdom
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Response to drug drug resistance,drug susceptibility/resistance,Response to drug,response to drug
Group 0 name Corresponds to the control (unexposed) group for case-control studies
No drug - Dimethyl sulfoxide only (DMSO only)
Group 1 name Corresponds to the case (exposed) group for case-control studies
Entacapone High Concentration(ENT-High) after 24 hrs of incubation - Donor 2
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Entacapone High Concentration(ENT-High) after 24 hrs of incubation refers to the drug concentration given to donor 2 after twenty-four hours of incubation. Entacapone is a catechol-O-methyltransferase (COMT) inhibitor that acts by preventing the degradation of levodopa. It is the main drug used in the treatment of Parkinson’s disease. High concentration was based on estimated colon concentration and was included to better reflect the exposure of gut microbes to drugs in the large intestine.
Group 1 sample size Number of subjects in the case (exposed) group
3
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
3 months

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
Not specified
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
raw counts
Statistical test
DESeq2
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Inverse Simpson Modification of Simpsons index D as 1/D to obtain high values in datasets of high diversity and vice versa
decreased
Richness Number of species
decreased

Signature 1

Needs review

Curated date: 2024/11/22

Curator: KateRasheed

Revision editor(s): KateRasheed

Source: Supplementary Table 6

Description: Differential abundance of taxa between No drug and ENT-High in Donor 2 after 24hrs of incubation.

Abundance in Group 1: increased abundance in Entacapone High Concentration(ENT-High) after 24 hrs of incubation - Donor 2

NCBI Quality ControlLinks
Lachnospiraceae FCS020 groupLachnospiraceae FCS020 group
Lacticaseibacillus
Actinomyces
Oscillospiraceae incertae sedis
unclassified Oscillospiraceae
Raoultibacter
Collinsella
Mogibacterium
Holdemanella
Granulicatella
Colidextribacter
Butyricicoccus
Marvinbryantia
Family XIII AD3011 groupFamily XIII AD3011 group
Barnesiella
Faecalibacterium
Oscillospiraceae UCG-002Oscillospiraceae UCG-002
Veillonella
Lachnospira eligens
Lachnospiraceae UCG-001Lachnospiraceae UCG-001
Blautia
Escherichia/Shigella sp.
Citrobacter
unclassified Enterobacteriaceae
Hafnia-ObesumbacteriumHafnia-Obesumbacterium
Bifidobacterium
Lachnospira
Terrisporobacter
unclassified Lachnospiraceae
Megasphaera
Agathobacter
Acidaminococcus

Revision editor(s): KateRasheed

Signature 2

Needs review

Curated date: 2024/11/22

Curator: KateRasheed

Revision editor(s): KateRasheed

Source: Supplementary Table 6

Description: Differential abundance of taxa between No drug and ENT-High in Donor 2 after 24hrs of incubation.

Abundance in Group 1: decreased abundance in Entacapone High Concentration(ENT-High) after 24 hrs of incubation - Donor 2

NCBI Quality ControlLinks
Prevotella_7Prevotella_7
Coprococcus
Prevotella_9Prevotella_9
Parabacteroides
Sutterella
Bacteroides
Blautia
unclassified Lachnospiraceae
Anaerostipes
uncultured Lachnospiraceae bacterium
Faecalibacterium
Fusicatenibacter
Erysipelotrichaceae UCG-003Erysipelotrichaceae UCG-003
Thomasclavelia
Alistipes
unclassified RF39unclassified RF39
Butyricimonas
Lachnospiraceae NK4A136 groupLachnospiraceae NK4A136 group
Colidextribacter
Unclassified Clostridia vadinBB60 groupUnclassified Clostridia vadinBB60 group
Oscillibacter
Christensenellaceae R-7 groupChristensenellaceae R-7 group
uncultured Oscillospiraceae bacterium
uncultured_unclassifieduncultured_unclassified
Slackia
Oscillospiraceae UCG-005Oscillospiraceae UCG-005
[Ruminococcus] torques

Revision editor(s): KateRasheed